+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial



Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial



Journal of Gastroenterology 52(4): 494-503



REACH evaluated ramucirumab in the second-line treatment of patients with advanced hepatocellular carcinoma. In the intent-to-treat population (n = 565), a significant improvement in overall survival (OS) was not observed. In patients with an elevated baseline α-fetoprotein (AFP) level (400 ng/mL or greater), an improvement in OS was demonstrated. An analysis of the Japanese patients in REACH was performed. An analysis was performed with the subset of the intent-to-treat population enrolled in Japan (n = 93). The median OS was 12.9 months for the ramucirumab arm (n = 45) and 8.0 months for the placebo arm (n = 48) [hazard ratio (HR) 0.621 (95 % confidence interval (CI) 0.391-0.986); P = 0.0416]. The median progression-free survival was 4.1 months for the ramucirumab arm and 1.7 months for the placebo arm [HR 0.449 (95 % CI 0.285-0.706); P = 0.0004]. The objective response rates were 11 % for the ramucirumab arm and 2 % for the placebo arm (P = 0.0817). The grade 3 or higher treatment-emergent adverse events occurring in more than 5 % of patients with a higher incidence for the ramucirumab arm (n = 44) than for the placebo arm (n = 47) were ascites (7% vs 2 %), hypertension (7 % vs 2 %), and cholangitis (7 % vs 0 %). In patients with a baseline AFP level of 400 ng/mL or greater, the median OS was 12.9 months for the ramucirumab arm (n = 20) and 4.3 months for the placebo arm (n = 22) [HR 0.464 (95 % CI 0.232-0.926); P = 0.0263]. In the Japanese patients in REACH, ramucirumab treatment improved OS, including in patients with a baseline AFP level of 400 ng/mL or greater; improvements in progression-free survival and objective response rate were also demonstrated. The safety profile of ramucirumab was acceptable and well tolerated in Japanese patients. ClinicalTrials.gov identifier NCT01140347.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058688410

Download citation: RISBibTeXText

PMID: 27549242

DOI: 10.1007/s00535-016-1247-4


Related references

O2-8-1Ramucirumab (Ram) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (Hcc): Japanese subgroup analysis of the phase Iii Reach trial. Annals of Oncology 26(Suppl 7): vii94.3-vii94, 2015

Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score. JAMA Oncology 3(2): 235-243, 2017

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet. Oncology 16(7): 859-870, 2015

Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade. Journal of Hepatology 64(2): S693-S694, 2016

O-005 * Ramucirumab (RAM) as second-Line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: comprehensive results from the randomized phase III REACH study. Annals of Oncology 26(Suppl 4): Iv109-Iv109, 2015

Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis. Oncotarget 7(46): 75482-75491, 2016

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. European Journal of Cancer 81: 17-25, 2017

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. Oncology 20(2): 282-296, 2019

Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer 19(3): 927-938, 2016

Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial. Clinical Lung Cancer 19(3): 270-279.E3, 2018

Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein. Lancet. Oncology 20(4): E191, 2019

L03Ramucirumab (Ram) as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (Hcc) Following First-Line Therapy with Sorafenib: Analyses from the Randomized Phase Iii Reach Study. Annals of Oncology 26(Suppl 6): vi.80-vi, 2015

Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer. Asia-Pacific Journal of Clinical Oncology 14(3): 204-209, 2018

Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment. Hepatology Research 49(9): 1054-1065, 2019

Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer. Journal of Gastroenterology and Hepatology 31(3): 581-589, 2016